Select one or more of the webinars you wish to view and click the "Download" button. You will be asked to fill out a brief form in order to receive the webex links.


APR 2014 03
Transform the future of oncology with genomics
More Info +

Illumina next-generation sequencing (NGS) and microarray technologies are revolutionizing cancer research, enabling cancer variant discovery and detection, tumor profiling, and gene expression studies. Our expanding oncology portfolio includes new tools that aid the discovery, identification, and analysis of cancer variants.

Join us for a review of recent advances in Illumina sample-to-data solutions, from whole-genome, RNA, and targeted sequencing, to epigenetic analysis, germ line risk assessment, and cytogenetics. Learn how these transformative solutions are now delivering relevant oncological information into the hands of translational and clinical researchers. Hear about groundbreaking developments in cancer genomics from around the world, including:

  • Whole-genome and targeted sequencing of DNA and RNA
  • Epigenetic analysis, germ line risk investigations and cytogenetics
  • Single cell sequencing to understand tumor heterogeneity
  • Deep sequencing of circulating nucleic acids as non-invasive bio markers


Cancer Genomics
MAR 2014 26
The Human Virome in Health and Disease
More Info +

The human virome—the collection of all the viruses within the human body—includes chronic and transient infections, endogenous retroviruses, and large bacteriophage populations that prey on human-associated bacteria. Recent studies have revealed that the human virome contains a high degree of variation. After sequencing and analyzing virome samples from healthy and diseased individuals on an Illumina HiSeq® System, researchers found that most viral contigs are novel sequences and viral communities vary greatly between individuals.

These findings provide insight into the variation between viromes, indicating that factors such as diverse viral predators, rapid viral evolution within the human body, and disease can affect the virome community. This webinar discusses the viral communities inhabiting the human body and how the virome affects human health.

Microbiology & infectious disease
MAR 2014 11
Karyomapping—A Rapid PGD Solution for Single-Gene Disorders
More Info +

Preimplantation Genetic Diagnosis (PGD) can be used where there is a risk of severe genetic disorders being inherited from parents, whether the couple has a family history of a genetic disorder or has a child affected by a genetic disease. Currently, PGD is often performed by examining the inheritance of short tandem repeats (STRs) adjacent to specific disease loci. Unfortunately, this method is complex and must be developed individually for each genetic disorder and each couple, making it time-consuming and limiting availability.

Karyomapping offers a faster, more accurate, and robust alternative to STR analysis for PGD. Using genome-wide linkage-based analysis, karyomapping detects single-gene disorders from as little as a single embryonic cell. Embryos that do not carry the defective gene can be identified and selected for transfer and subsequent implantation.

Join Professor Alan Handyside, one of the pioneers of karyomapping, and Dr. Alan Thornhill as they introduce the Illumina karyomapping solution, including the Infinium HumanKaryomap-12 BeadChip. This karyomapping assay targets ~300,000 of the most informative genomic markers resulting in comprehensive genome-wide analysis at the single-cell level.

Reproductive & Genetic Health
MAR 2014 03
16S rRNA sequencing: From DNA extraction to entire microbial community analysis
More Info +

Working closely with the microbial community, we’ve developed a powerful next generation sequencing solution that enables researchers to analyze an entire microbial community within a sample, including species that may not be identified otherwise. This culture-free method eliminates the time and expense involved in growing pure cultures and individually sequencing each type of bacteria.

Discover how you can leverage these next generation sequencing solutions to initiate and accelerate your own 16S rRNA studies.

Topics include:

  • An overview of the streamlined 16S rRNA metagenomics sequencing protocol
  • Discussion of analysis options with MSR and BaseSpace
  • Live demonstration of the BaseSpace 16S app
  • Case study conversation
    • A comparison of 16s metagenomic sequencing on MiSeq and 454
    • Desert tortoise conservation – disease surveillance and diagnosis
Microbiology & infectious disease
FEB 2014 18
NextSeq 500 Delivers Power and Flexibility for Cancer and Genetic Disease Studies
More Info +

GS-based variant detection is central to cancer and genetic disease studies, with the promise of enabling more accurate prognoses and more effective therapeutics. Using whole-genome, whole-exome, and RNA sequencing, large international projects such as The Cancer Genome Atlas (TCGA) and others have contributed greatly to the catalog of somatic driver mutations that underlie tumorigenesis and progression. The methods that powered these research strategies are now accessible to every lab with the NextSeq 500 system. Combining the power and accuracy of Illumina high-throughput sequencing with the speed, simplicity, and affordability of a desktop system, NextSeq 500 delivers multiple sequencing applications on one platform. The NextSeq 500 System is capable of sequencing a whole human genome at 30× in one run, and delivers exceptional workflow flexibility for other sequencing applications, including exome and RNA sequencing. Simple, cartridge-based reagents and configurable run modes allow researchers to quickly tailor experiments ranging from gene expression to complex whole-transcriptome profiling, on a single NGS system. Workflow improvements and expansions, including sample prep automation, run monitoring, data analysis, and storage using cloud or onsite options, will continue to improve the utility of NGS for the research needs of today and tomorrow.

Human Genetics & Genetic Disease
FEB 2014 04
Somatic Variant Discovery and Translation in Cancer Genomics – Next Generation Sequencing Solutions
More Info +

Next-generation sequencing (NGS)-based detection of somatic variants in tumor samples is a powerful tool to uncover the molecular drivers associated with different cancer types. This technology holds promise to enable more accurate prognoses and more effective therapy decisions – the foundation necessary to achieving precision medicine. Using whole-genome, whole-exome, and RNA-Seq, large international projects, such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC), have contributed greatly to the catalog of somatic driver mutations that underlie tumorigenesis and progression in many common and rare cancers. These discoveries provide basic research and drug development communities direction to focus on the targets of greatest impact in the war on cancer. In the clinical research and oncology communities, similar sequencing strategies have emerged as a powerful weapon to further understand variation in the clinical course of various cancer types. 

These strategies are now accessible to every lab with Illumina’s new NextSeq 500 system. Using a powerful combination of sample preparation, sequencing, and informatics methods, Illumina now enables researchers to perform the same groundbreaking cancer analysis pioneered by groups such as TCGA and ICGC in their labs. This experimental design is more accessible than ever before. Join us to learn how researchers are using this comprehensive approach to continue to discover the biology of cancer and translate discoveries faster than ever before.

Cancer Genomics
NOV 2013 26
Creating, Expanding, and Streamlining Your Next-Generation Sequencing Portfolio using the TruSight™ One Sequencing Panel and VariantStudio
More Info +


Building a comprehensive sequencing portfolio with individual panels for each condition of interest presents numerous developmental and managerial complications. To help you overcome this challenge and streamline your sequencing portfolio while maximizing assay offerings, Illumina offers the TruSight One Sequencing Panel. TruSight One is a single, large sequencing panel targeting more than 4,800 genes and covering 12 Mb of genomic content. Combining TruSight One with the VariantStudio data analysis tool creates the simplest sample-to-report workflow that can replace dozens, if not hundreds, of small, individual sequencing panels and assays. The unmatched coverage uniformity of TruSight One facilitates high levels of multiplexing, enabling sequencing of trios on a single MiSeq flow cell and 36 samples on a single HiSeq flow cell.

Human Genetics & Genetic Disease:Sequencing:Software
OCT 2013 29
GenomeStudio Software for Automated Polyploid Clustering
More Info +

Many plant species are polyploid organisms with multiple homologous chromosomes, which often complicates genetic analysis. Illumina has developed the GenomeStudio Polyploid Clustering Module, which features powerful DBSCAN and OPTICS algorithms, to help researchers analyze genotyping data from polyploid genomes.

This webinar, presented by Cindy Lawley, Ph.D., Global Agriculture Consortia Program Manager at Illumina, demonstrates how to use the Polyploid Clustering Module. Topics include: starting a project, optimizing cluster detection sensitivity, manually adjusting clusters, importing cluster positions, and exporting cluster data. The webinar also covers analysis of the wheat genome to demonstrate how to use the Polyploid Clustering Module to study a complex genome.

Agriculture Genomics
OCT 2013 24
Molecular Pathology Reimbursement: Outcome of the 2013 Medicare Gapfilling Process
More Info +

This webinar summarizes the outcome of the recently concluded Medicare gapfilling process for 114 new molecular pathology (MoPath) codes that were implemented in 2013. The presentation will address the final 2013 regional rates for these codes, as well as the implications for national payment rates in 2014. We will then look ahead to additional upcoming changes in the molecular diagnostic reimbursement landscape and the potential impact on clinical laboratories.

OCT 2013 11
Personal genome sequencing and the future of healthcare, My experience at Understand Your Genome
More Info +

Illumina coined a new verb – “get genomed” – in support of Understand Your Genome, an event where participants get “genome-sequenced” and “genome-educated.” During this webinar, I will discuss my personal experience at Understand Your Genome, where I had my genome sequenced, received the raw data on an iPad, and viewed reports in the MyGenome App. Join me in a discussion of the role of whole genome sequencing in modern medicine and its impact on the future of health care.

Human Genetics & Genetic Disease
SEP 2013 10
Deep sequencing of HIV: Detection of Drug Resistance Variants and Tracking of Viral Haplotypes
More Info +

HIV drug resistance testing has become an integral part of HIV clinical care. Commercially available genotypic assays identify drug resistance mutations through population sequencing of regions of the HIV protease and reverse transcriptase genes. However, these assays are insensitive to drug resistance variants when present at levels comprising less than 10 to 20 percent of the virus population.

By contrast, ultradeep sequencing allows the identification of HIV nucleotide variants and variant haplotype signatures present at <1% in patient samples. Tracking of viral haplotypes, which requires long-sequence read lengths, is particularly useful in determining whether sequentially expressed dual infections are the consequence of viral evolution, co-infection, or superinfection.

This webinar presents insight into the characterization of HIV by next-generation sequencing, including data obtained from a comparison of HIV drug-resistance variant detection in a 465-base region of HIV reverse transcriptase by the Illumina MiSeq and Roche 454 GS FLX+ platforms.

Microbiology & infectious disease
AUG 2013 15
Implementing Informatics Solutions to Support Genomics
More Info +

The Human Molecular Genetics Center at the Medical College of Wisconsin has implemented an efficient informatics solution to support genomics sequencing runs using Illumina systems. Jaime Wendt Andrae will discuss how they implemented the beta-version of Clarity Run Manager to enable sample tracking and automation of Illumina sequencing runs. Aubree Hoover will briefly introduce this new version of Clarity Run Manager, a free solution for managing projects and samples, and easily creating sample sheets for Illumina instruments.

AUG 2013 07
Ground-breaking study, identifying a causal gene mutation for two dissimilar neurological diseases
More Info +

Dr. Bryan Traynor and his team participated in a ground-breaking international study, identifying a causal gene mutation responsible for two dissimilar neurological diseases, ALS and FTD. As members of a worldwide consortium, his research team used next-generation sequencing to identify a large hexanucleotide repeat that disrupts the C9ORF72 gene located on chromosome 9. The mutation accounts for approximately 40% of all familial cases of ALS and FTD in European and North American populations, and also ~1% of Alzheimer&rsquo;s disease cases. ALS, also known as Lou Gehrig&rsquo;s disease, is a fatal neurodegenerative disorder that leads to rapidly progressive paralysis and respiratory failure. Frontotemporal dementia (FTD) is the most common form of dementia in the population under the age of 65.<br /><br />This landmark discovery has impacted how these neurological disorders are diagnosed, investigated and perceived. It also provides a distinct therapeutic target for gene therapy efforts aimed at ameliorating these diseases.

Human Genetics & Genetic Disease
JUL 2013 17
Real Time PCR Experimental Design and Analysis Amplified with NuPCR Reagents
More Info +

Quantitative Real-Time PCR (qPCR) has been the technique of choice for gene expression analysis studies for decades. Although effective, current probe-based assays can exhibit cross-reactivity issues, require tedious design procedures, and involve expensive reagents. NuPCR reagents constitute a novel approach that uses a unique NuZyme™ complex for cost-effective, sensitive, and specific qPCR on any Real-Time PCR instrument. In addition, web-based DesignStudio™ software is available to simplify assay design and ordering. 

In this webinar, Gothami Padmabandu will discuss NuPCR chemistry and the ease of designing duplexed assays. In addition, experimental design and data analysis using NuPCR reagents in a number of different qPCR applications will be presented.

JUN 2013 19
Identification of rare disease-causing variants using next-generation sequencing
More Info +

Activating mutations in the GNAQ gene can lead to Sturge-Weber Syndrome, a rare disease affecting 1 in 20,000 people. Mutations in this same gene can also cause port-wine stain birthmarks affecting 1 in 333 individuals. In this presentation, Dr. Jonathan Pevsner of Kennedy Krieger Institute will describe his lab's research using whole-genome and targeted resequencing to identify causative variants of these somatic mosaic conditions. The presentation will also discuss the use of Illumina's TruSight Autism content set for the detection of variants associated with Autism Spectrum Disorder. 

Human Genetics & Genetic Disease
JUN 2013 13
Latest Developments in Molecular Pathology (MoPath) Rate Setting
More Info +

In May 2013, the Centers for Medicare and Medicaid Services (CMS) proposed new payment rates for the new MoPath codes. Many laboratories are concerned that these rates undervalue key test areas, including molecular cytogenomic, inherited disease, and cancer testing.
July 8 is the final deadline to respond to these rates and propose new values.

In this webinar, you will learn:

● About the latest developments in MoPath rate setting
● How to participate in the rate setting process to ensure appropriate reimbursement for future molecular diagnostic tests
● How and when to respond to the current rate proposal

MAY 2013 30
Sequencing analysis of tissue samples: Fresh frozen vs. FFPE
More Info +

We'll discuss:

  • Analyzing small sample sizes of FFPE material
  • Obtaining FFPE results that are consistent with fresh-frozen results
  • Specially developed tools for comparing results
Cancer Genomics
MAY 2013 22
Assembling and Analyzing Illumina Data in DNASTAR Lasergene Software
More Info +

Join us to learn how to simplify your data analysis workflows for Illumina sequencing experiments. DNASTAR Lasergene software is a set of genomic assembly and analysis tools that provide a simple, yet highly flexible environment for RNA profiling, reference-guided and de novo sequence assembly, and many other workflows. During this presentation, Matthew Keyser of DNASTAR will demonstrate sequence assembly and analysis of Illumina data using Lasergene. The demonstration will include:

  • Multiple exome assembly and comparison
  • RNA-Seq alignment and analysis
  • Microbial genome assembly with gap closure
  • SeqMan NGen for de novo genome assembly on the Illumina BaseSpace® platform
MAY 2013 02
Exploring the Home, Hospital, and Human Microbial Interactome – The H3MP Study
More Info +

Through next-generation sequencing, microbial genomic research is accelerating the pace of discovery–rapidly expanding our understanding of microbial function and interactions.

Metagenomic and microbiome studies provide researchers deep insight about the microbes that populate our surroundings, infrastructure, and built environments. In this webinar, Dr. Jack Gilbert will present initial findings from the Hospital Microbiome Project. The goal of this ongoing initiative is to characterize the taxonomic composition of surface, air, water and human-associated communities in a new hospital—starting from the introduction of patients to major surgical procedures. Please join us to see Dr. Gilbert present preliminary data and discuss what his team has discovered from this exciting endeavor.

APR 2013 17
Optimizing the Utility of Forensic Human Mitochondrial DNA Analysis
More Info +

Our laboratory has developed a protocol designed to generate whole mitochondrial genome (mt-genome) sequencing data from robust DNA samples, such as those obtained from buccal swabs and blood stains. This approach uses a long PCR amplification technique with two overlapping primer sets, covering the entire human mt-genome. Pooled amplicons are prepared with the Nextera XT™ DNA Sample Preparation Kit and rapidly sequenced on the MiSeq system, generating high-throughput sequencing data that can be quickly analyzed using the on-board software as well as third-party software tools. Data quality is sufficient to easily determine the presence of expected polymorphisms in the samples. In addition, the deep sequencing results on carefully prepared mixtures are able to detect the presence of minor variants at the expected positions, providing a heightened level of detection of minor sequence variants. Results from single source and mixed DNA samples underscore the value and sensitivity of Illumina sequencing data, relative to Sanger sequencing, in providing increased resolution of forensic mtDNA samples.

Forensic Genomics
MAR 2013 14
Genomic Sequencing in the Clinical Laboratory: Lessons Learned and Best Practices
More Info +

Genome sequencing for clinical use has the potential to reduce diagnostic odysseys, refine diagnostic evaluations, increase our understanding of prognoses, and improve patient care. In order to establish whole-genome sequencing as another tool at the physician's disposal, several components must be carefully developed and evaluated. Among these are physician and patient support, informed consent, secure data management, and, critically, the analytical quality of the data generated for clinical interpretation. As we move towards an era of genomic testing and increase our knowledge of the genome, analytical validity becomes increasingly important. In this webinar we discuss the lessons and best practices learned by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.

DEC 2012 11
Learn How the Illumina Genome Network (IGN) Has Been Instrumental in Providing Fast, Reliable Whole Human Genome Sequencing Data
More Info +

Chris Mason describes how he used the Illumina Genome Network (IGN) for low input, whole-genome sequencing of rare clinical cases with extreme phenotypes from the NIH's Undiagnosed Disease Program (UDP) and a consanguineous family with neural-tube defects (NTDs). For all sequenced samples, the IGN data provided high coverage across the genome, including regulatory regions like promoters and enhancers, allowing the research team to pinpoint likely genes for the disease phenotypes. A comparison of output data from IGN software suite (CASAVA/GROUPER) to SAMtools/GATK revealed a high overlap of SNVs and indels between software platforms. The variants specific to each software suite showed higher Ti/Tv ratio. Overall, the results highlight the ease and speed of whole-genome sequencing services for identifying disease phenotypes. The genetic data can be combined with other biological modalities (transcriptional, epigenetic, proteomic) to function as a systems biology approach for personalized medicine.

DEC 2012 07
Next-gen sequencing at the touch of a button
More Info +

Explore how the MiSeq® system can empower your research. As the only fully integrated personal sequencer, MiSeq delivers a streamlined solution that takes you from rapid sample prep through automated data analysis and storage in the BaseSpace™ cloud. Sequencing doesn't get any easier than this.

In this webinar, you'll discover why Miseq is the most accurate and easiest to use benchtop sequencer. Take a tour of the system and learn about:

  • Accomplishments by researchers in your field who are using MiSeq in their labs
  • Updates to our growing applications portfolio
  • Advancements to sequencing's fastest and easiest workflow
  • Recent improvements to our sequencing-by-synthesis chemistry for faster, longer reads, and expanded capability for applications
DEC 2012 05
Transcriptome analyses in individual cells using Smart-Seq
More Info +

Methods for global gene expression analysis in individual cells have important applications in biology and medicine. This webinar describes the Smart-Seq protocol for polyA+ RNA analysis, applicable at single-cell levels. Compared to existing methods, the Smart-Seq protocol has improved read coverage across transcripts, significantly enhancing analysis of alternative transcript isoforms and improving SNP identification. The sensitivity and quantitative accuracy of the Smart-Seq method for single-cell transcriptomics have been evaluated with total RNA dilution and spike-in RNAs. This method has been proven using cancer cell lines, circulating tumor cells from melanomas, and early embryonic cells. The Smart-Seq protocol provides a robust method for addressing fundamental biological questions that require transcriptome profiling in rare or single cells.

DEC 2012 04
Education in a Next-Gen World: Considerations for Whole-Genome Sequencing
More Info +

The advent of clinically available whole-genome sequencing (WGS) offers an opportunity to educate ourselves and our colleagues about the benefits and challenges of genomic testing. In addition, we need to consider how we can best approach particular audiences, as well as the appropriate level of information to give each audience.

NOV 2012 28
Outbreak - The Sequel: Using Next-gen Sequencing to Unravel Outbreaks of Infectious Disease
More Info +

When an infectious disease outbreak occurs, public health officials attempt to identify where it started and how it spread so that they can initiate appropriate control and prevention strategies. Using a combination of field epidemiology (interviewing cases and controls) and molecular epidemiology (genotyping of bacterial or viral pathogens), they attempt to establish links between cases and develop a putative reconstruction of the outbreak. Unfortunately, the low resolution of molecular epidemiology techniques currently available to most reference microbiology laboratories cannot provide detailed information on the underlying transmission dynamics within an outbreak. However, next-generation sequencing offers exciting new possibilities for tracking disease outbreaks with high resolution. Over the course of an outbreak, a small amount of genetic variation accrues in a pathogen's genome as a result of mutations. By tracking the presence or absence of these mutations in all pathogen genomes from a given outbreak, it is possible to identify where particular variants arose and trace person-to-person transmission events. This webinar will provide an introduction to this emerging field of genomic epidemiology, highlighting the application of this approach to reconstruct outbreaks of tuberculosis in British Columbia, Canada.

NOV 2012 14
Fast Annotation of Human Genomes on the Illumina HiSeq® 2500 System
More Info +

The HiSeq 2500 System delivers incredible accuracy, throughput, and total workflow turnaround time for high-throughput applications. The simple whole-genome sequencing workflow allows you to quickly go from DNA to annotated variants for interpretation and decision-making. This webinar will highlight the latest system advances:
• New library preparation kits that enable low amounts of DNA input, including FFPE samples
• Improved sequencer performance
• The latest alignment/annotation and interpretation software

OCT 2012 02
Evolving tools for understanding the functional genome: RNA-Seq and the ENCODE Project
More Info +

RNA-Seq is a powerful tool for studying various aspects of RNA biology, including expression levels, alternative splicing, RNA editing, and gene discovery. Though RNA-Seq has long been in use, robust and easy methods for generating strand-specific libraries and libraries from total RNA samples have not been commercially available. The new Illumina Tru-Seq Strand-specific Total RNA-Seq kits facilitate the generation of high quality libraries via a simple, rapid, and familiar workflow. I will present modENCODE data generated using these new kits and compare the results to those generated from libraries prepared using previous Illumina RNA-Seq kits and the same RNA samples. Specifically, I will discuss the degree of strandedness, evenness of coverage, and discovery of transcribed regions not identified using poly(A)-selected RNA-Seq libraries.

AUG 2012 01
Integrated Analysis Tools for Next-Generation Sequencing Data
More Info +

Avadis NGS is an integrated platform that provides analysis, management, and visualization tools for next-generation sequencing data. It supports extensive workflows for RNA-Seq, small RNA-Seq, DNA-Seq, and ChIP-Seq experiments. The typical analysis workflow in Avadis is composed of four parts:

1. Data Import: supports seamless data importing from the MiSeq run folder, importing of FASTQ files and alignment using the COBWeb algorithm, or direct importing of SAM/BAM files.

2. Quality Control: generates various quality control plots and filter steps to ensure the quality of reads for analysis.

3. Analysis: provides core analysis steps specific to each workflow, along with intuitive organization and visualizations.

4. Biological Contextualization: enables investigation of interesting genes for GO enrichment, GSEA, network and pathway analysis.

JUL 2012 11
Illumina IGN Webinar Series: Webinar Three - Useful Bioinformatics for Characterizing Somatic Mutations of an Oral Cancer Using a Whole-Genome Sequencing Technology
More Info +

See how expert bioinformaticians have used in-house and open-source tools to re-analyze and further interrogate IGN data. The presentation will describe the computational requirements, walk you through a reanalysis pipeline, and highlight the benefits of working with universal, industry-standard file formats.

JUN 2012 21
STAT-Seq: Rapid WGS on the HiSeq® 2500 - Implications for a Neonatal Intensive Care Unit
More Info +

Monogenic diseases are frequent causes of neonatal morbidity and mortality. Over 3,500 monogenic diseases have been characterized, many of which feature clinical and genetic heterogeneity. Since disease presentation at birth is often undifferentiated, there is an immense need for molecular diagnosis in infants. Disease progression in newborns is often fast and heterogeneous, so molecular diagnosis must occur rapidly for relevant clinical decision making. Here, we describe 50-hour differential diagnosis of genetic disorders by whole genome sequencing (WGS), featuring substantially automated bioinformatic analysis. This is intended to be a prototype for deployment in neonatal intensive care units.

JUN 2012 20
Illumina IGN Webinar Series: Webinar Two - Expanding your Current WGS Knowledge
More Info +

Get a head start on data analysis and learn guidance on best practices used by the IGN. This presentation will demonstrate how popular open-source tools can be used to perform further analysis of alignment and variant data. For users with some in-house informatics expertise and experience with large data sets, this information will help you expand on what you already know.

JUN 2012 07
Analyzing Microbes and Complex Microbial Populations with Next-Generation Sequencing
More Info +
Speaker: Abizar Lakdawalla, Ph.D., Illumina, Inc.

This webinar will introduce the latest advances in next-generation sequencing for analyzing microbial genomes and transcriptomes, and will present key studies highlighting this technology.

Sequencing microbial genomes provides a comprehensive understanding that no other method can provide. For example, it is now possible to achieve single base resolution of the bacterial chromosome, and detailed sequence of all extrachromosomal elements, including plasmids and phages. Improvements in next-generation sequencing methods now enable routine whole bacterial genome sequencing in a single day. Assembling the genome from sequencing reads can be easily performed on a desktop computer, allowing high resolution classification of bacterial subtypes. Many important features, including resistance, virulence, and pathogenicity, can be examined simultaneously with high accuracy. In addition to genomic experiments, next-generation sequencing can be used to analyze the complete transcriptome of microbes for interpretation of gene structure and regulation. Sequencing complex microbial populations or metagenomes provides a comprehensive census of species within samples, including those that cannot be cultured or phenotyped. Subtle changes in microbial populations resulting from, or predictive of, changes in the health status of a patient can be assessed easily and accurately with next-generation sequencing.

MAY 2012 31
Illumina IGN Webinar Series: Webinar One - Getting Started with WGS Data Analysis
More Info +

In this webinar, IGN Informatics partners will describe preconfigured solutions that automate data analysis, allowing you to go directly to biological analysis. You'll hear from three leading IGN partners, Knome, Ingenuity, and Diagnomics, who offer analysis solutions uniquely suited for the needs of IGN customers. Ideal for labs with no in-house informatics expertise, these solutions help facilitate all steps of the downstream analysis, including annotation, filtering, and multi-sample analysis.

Rapid Identification of Causal NGS Variants using Ingenuity Variant Analysis

  • Karen Lavery, Ph.D., Field Application Scientist, Ingenuity
  • Brent Applegate (additional panelist)

Human Whole Genome Interpretation...for Humans

  • Nathan Pearson, Ph.D., Director of Research, Knome, Inc.

Genetic Analysis, Research to Bedside

  • Jongsun Park, Ph.D., Senior Scientist & Group Leader, Diagnomics
  • Min Seob Lee, Ph.D. (additional panelist)
MAY 2012 17
Miseq vs. Ion Torrent PGM in a Bacterial Research Lab - Workflow, Output, and Data Quality
More Info +

Dr. Tim Stinear has completed an in depth comparison of the MiSeq and Ion Torrent PGM to determine which technology is best suited to a microbial laboratory. Join Dr. Tim Stinear for a presentation comparing genome sequencing of three reference bacteria of varying DNA composition with the MiSeq personal sequencer using Nextera® library prep against the latest PGM chemistry and chips. In this webinar, Dr. Stinear will cover:

  • Rapid library preparation with Nextera
  • High-quality de novo bacterial sequencing with the MiSeq system
  • Comparison of data output and quality between MiSeq and Ion Torrent PGM
MAY 2012 03
Utility of whole-exome sequencing to elucidate the genetic basis of rare familial diseases
More Info +

The genetic basis for many rare, familial conditions has been difficult to elucidate due to the limited numbers of families affected and the small sizes of these families. Whole-exome sequencing provides an opportunity to identify the underlying basis for these diseases, some of which are novel presentations of known diseases and some of which are novel diseases themselves. In this webinar, Dr. Wendy Chung, M.D., Ph.D. will present several examples of how whole-exome sequencing has been successfully used to elucidate the pathogenesis of disease and how it directly affected patient care.

MAY 2012 01
Genotyping by Sequencing in Ag Species
More Info +

Dr. Jesse Poland, Ph.D.
Adjunct Assistant Professor, Department of Agronomy
Kansas State University, Kansas

Agriculture Genomics
APR 2012 26
How next-gen sequencing is revolutionizing cancer diagnoses
More Info +

Dr. Andrew Fellowes PhD FHGSA FFSc(RCPA)
Scientist in Charge, Molecular Pathology Diagnostic Development
Molecular Pathology Laboratory
Peter MacCallum Cancer Centre

The Peter MacCallum Cancer Centre in Melbourne is Australia’s only public hospital solely dedicated to cancer and home to the country’s largest cancer research group. In the Molecular Pathology Laboratory, Dr. Andrew Fellowes and his team are using the MiSeq system and TruSeq Amplicon - Cancer Panel to profile tumor samples for a wider range of mutations than is possible with traditional technologies.

Join us for a webinar with Dr. Fellowes as he discusses how his team is using the MiSeq system to:

  • Transition cancer diagnosis assays to next-generation technologies
  • Identify new mutations using ultra-deep amplicon sequencing
  • Perform comprehensive tumor profiling on 10,000 tumors over the next three years
Cancer Genomics:Sequencing
APR 2012 10
The Application of Next Generation Sequencing to Forensic Genetics
More Info +

Dr. Seth A. Faith, Ph.D.
Principal Research Scientist, Battelle Memorial Institute

The rapid speed increase and cost reduction of next-generation sequencing technologies is enabling powerful opportunities for multiplexing forensically relevant genotyping assays. In this study, massively parallel Illumina sequencing technology was used to interrogate human saliva samples for phenotypic and ancestry informative single nucleotide polymorphisms (SNPs), CODIS short tandem repeat (STR) loci, Y haplotype, mtDNA genome and oral microbiome analysis

MAR 2012 15
Comprehensive RNA-Seq Data Analysis on the Voila! Cloud-based Data Platform
More Info +

Jill Dombrauckas, Ph.D.
Director, Marketing, Prognosys Biosciences
Eugene Chudin, Ph.D.
Principal Scientist, Bioinformatics, Prognosys Biosciences

Explore how the Voila! data analysis platform can streamline data analysis in your lab. Prognosys Biosciences, an Illumina Certified Service Provider (CSPro), has created this unique platform by combining state-of-the-art tools with the computing power of Amazon's EC2 cloud. In this webinar, you'll see how bioinformatics specialists have optimized and validated the Voila! analysis algorithms to perform high-quality reduction of sequencing data using simulated and publicly-available datasets. Learn how the Voila! platform enables you to perform statistical analysis as part of an integrated workflow to discover significant associations with biological variables of interest.

You'll also learn how Voila! analysis can help you:
  • Increase the quality of mapping and the quantity of mapped reads
  • Yield more variant calls while maintaining high specificity (both SNPs and indels)
  • Detect splice junctions consistently and with high sensitivity and specificity
  • Focus on downstream biological analysis through fast, high-quality results provided in a uniform output format
  • Discover significant gene expression patterns

FEB 2012 21
Market Perspectives on Genomics: Payors and Hospitals
More Info +

Trisha Brown, MS, CGC, Vice President, Clinical Affairs
DNA Direct by Medco

Whole-genome sequencing presents both tremendous opportunities and challenges for health care. While clinical adoption is still limited by our knowledge of disease biology and complex genome-environmental interactions, situations are emerging where whole-genome sequencing and other broad-based genomics tests provide crucial information for patient care decisions.

In this webinar, you’ll learn about:

  • Payors’ perspectives, including employers and hospitals, regarding the emerging genomics market and the evolution of next-generation sequencing
  • Reimbursement and “readiness” with an emphasis on issues arising for pharmacogenetics
Translational Genomics
JAN 2012 06
Cost Effective Clinical Sequencing Made Possible by PerkinElmer
More Info +

Todd Smith, PhD, Scientific Leader
Geospiza, a PerkinElmer Company
Hugh Arnold, PhD, Senior Applications Scientist
Geospiza, a PerkinElmer Company

PerkinElmer has created a complete NGS workflow model that addresses rising genomics costs—allowing the company to provide complete, cost-effective genetic analysis solutions to its customers. As an Illumina Certified Service Provider (CSPro), PerkinElmer uses Illumina technology, its GeneSifter® LIMS and analysis software platforms, DNA sequencing services, and Caliper's SciClone and LabChip®GX instrumentation to make cost-effective genomics-based medicine possible.

In this webinar, PerkinElmer scientists will demonstrate how they provide affordable sequencing and genetic analysis solutions by:

  • Automating sample prep
  • Tracking, organizing, and processing data from whole genome, exome, RNA, methylation, and verification assays in automation frameworks

Validating systems for regulated environments using a risk-based approach built upon Good Automated Manufacturing Practice (GAMP) standards

DEC 2011 07
Applications of Next-Generation Sequencing in Clinical Care
More Info +

Rick Dewey, MD
Stanford Center for Inherited Cardiovascular Disease

Next-generation sequencing (NGS) presents both challenges and opportunities for clinical care. Dr. Dewey will share examples from his experience at Stanford, successful and otherwise, in which NGS has been applied to cases of familial cardiomyopathy, and other inherited conditions. Bring your questions for a Q&A session.

In this webinar, Dr. Dewey will discuss approaches to:

  • Data storage and management
  • Error identification and reduction
  • Disease risk encoded in the reference sequence
  • Variant validation
DEC 2011 01
Learn how the GenoLogics LIMS significantly improved operations at an Illumina FastTrack Sequencing Services lab in a few weeks
More Info +

Melissa Kamkar
Applications Scientist - Team Lead, GenoLogics
Christian Haudenschild
Vice President of Product Development, Illumina

In May 2011, the Illumina FastTrack Sequencing Services lab replaced its homegrown sample tracking database with the GenoLogics LIMS, which provides end-to-end information management of samples, tests, and results for next-generation genomics labs. Within a few weeks, the Illumina lab realized significant benefits and operational improvements with the preconfigured LIMS, eliminating bottlenecks and saving time.

In this webinar, we will present:

  • Operational and efficiency gains achieved at the Illumina lab after implementing the GenoLogics LIMS
  • Ease and speed of the implementation, and how the Illumina lab team was able to quickly adopt the LIMS
  • How the preconfigured LIMS is based on industry best practices, and how they affect sample prep, sample flow, QC, status updates, and work management
  • A Q&A session with Christian Haudenschild, Associate Director of Services at the Illumina FastTrack lab
NOV 2011 17
TruSeq Custom Amplicon: Learn How to Customize Content with DesignStudio
More Info +

Layla Katiraee, Ph.D.
Senior Scientist, New Product Transfer
Jonathan Bell
Product Manager, DNA Sequencing Applications

TruSeq Custom Amplicon (TSCA), the newest addition to the Illumina portfolio of fully customizable targeted resequencing solutions, is the fastest and easiest multiplexed amplicon assay that has been optimized for the MiSeq system. With the ability to generate up to 384 amplicons per sample, and indexes to support up to 96 samples per MiSeq run, TSCA provides an unprecedented level of multiplexing. Entire projects can now be accomplished in days, leveraging the long paired-end-read capability, speed, and high data quality of the MiSeq system.

TruSeq Custom Amplicon offers convenient probe design and ordering using DesignStudio, an easy-to-use online tool that provides dynamic feedback to optimize designs to suit any study need.

Please join us to learn how to navigate DesignStudio, design content, and order amplicon panels in just a few steps.

In addition, the following topics will be covered:

  • TruSeq Custom Amplicon workflow and performance metrics
  • DesignStudio: Watch a live demonstration
  • Best practices for customizing content
NOV 2011 03
Optimization of Illumina mRNA-Seq and Conversion to a User-Friendly Analysis Solution
More Info +

Dr. Joel Parker
Principal Scientist, Expression Analysis
Gabe Rudy
Vice President of Product Development, Golden Helix

RNA sequencing is increasingly recognized for its performance benefits relative to gene expression microarrays. Advantages include unbiased content, precise quantification, detection of novel isoforms, and detection of nucleotide variation. The primary goal of this study was to determine what factors influence sequencing performance, and how this performance compares to that of gene expression microarrays.

In this webinar, we will present:

  • An RNA sequencing experimental design strategy that is robust, repeatable, and reproducible.
  • A fully integrated, user-friendly solution for extracting biological relevance from RNA-Seq data.
  • A cloud-based analysis pipeline, designed for biologists without extensive bioinformatics training.
OCT 2011 10
Using IPA® to analyze Illumina RNA-Seq data reveals abundance-specific biological signatures in Alzheimer's Disease
More Info +

Darryl Gietzen, Ph.D.
Field Application Scientist, Ingenuity Systems

IPA was used to interpret Alzheimer's disease biology by comparing Illumina RNA-Seq data from Alzheimer's disease (AD) and normal brain samples. This analysis revealed very specific biological changes in certain classes of transcript expression, demonstrating how the unique benefits of RNA-Seq can help characterize disease changes.

In this webinar, we will discuss how:

  • IPA maximizes the value of RNA-Seq data analysis
  • Grouping and analyzing all significantly changed genes in RNA-Seq data can provide pathway level information
  • The sensitivity and accuracy of RNA-Seq enables pathway analysis on a subset of genes to elucidate more subtle biological changes
SEP 2011 01
TruSeq Custom Enrichment: Learn How to Customize Content with DesignStudio
More Info +

Scott O'Brien
Sr. Product Manager, DNA Sequencing Applications
John Izzo, Ph.D.
Sr. Scientist

Discover how you can easily customize your studies, dramatically reduce hands-on time, and increase throughput with TruSeq Custom Enrichment. The latest addition to Illumina's targeted resequencing portfolio, TruSeq Custom Enrichment offers an integrated, end-to-end solution based on proven next-generation technology. Combined with DesignStudio, an interactive, web-based tool, the TruSeq Custom Enrichment workflow is the most efficient, scalable solution available today.

Please join Illumina scientists to learn more about:

  • Targeted resequencing workflows and performance metrics
  • DesignStudio; watch a live demonstration
  • Best practices for easily designing content to optimize coverage
JUL 2011 28
Moving Forward on a Framework for Analysis of Diagnostic and Incidental Results of Whole Exome / Genome Sequencing
More Info +

Jonathan S. Berg, MD, PhD
Assistant Professor, Department of Genetics
Member, Lineberger Comprehensive Cancer Center
Associate Director, Carolina Center for Genome Sciences

One of the major obstacles to the implementation of whole genome approaches for genetic medicine is the ability to extract clinically meaningful information from the vast number of variants that are identified. Our group has established parallel informatics pipelines for the diagnostic evaluation of genome sequence data, based on genes with known association with genetic disorders, and assessment of incidental findings, based on their clinical utility or lack thereof. This presentation will provide a brief introduction to next-generation sequencing approaches to detect germline mutations in patients, a review of the literature regarding clinical interpretation of genomic sequencing data, an overview of our proposed interpretive framework, and examples from our initial analyses of whole genome sequences from patients enrolled in a research study at UNC.

JUN 2011 21
Optimized Alignment and Variant calling using Illumina's CASAVA 1.8 Software
More Info +

Eric E. Smith, Ph.D.
Bioinformatics Scientist, Illumina

Interested in the latest features of Illumina's sequence analysis software? In this webinar you will learn about the key changes in CASAVA v1.8 and other bioinformatics tools from Illumina, including:

  • ELANDv2e: Improvements in the alignment algorithm
  • Enhancements in variant calling
  • New support for industry-standard file formats
  • Support for other useful bioinformatics tools
  • By attending this webinar, you will receive the latest details on bioinformatics software from Illumina and you will also learn how these can improve the quality and accuracy of Illumina sequencing datasets.
MAY 2011 26
Introduction to RNA Sequencing Data Analysis
More Info +

Amy Bouck-Knight, Ph.D.
Bioinformatics Support Scientist, Illumina Technical Support

Interested in leveraging the power of Illumina RNA sequencing in your research, but unsure of what data analysis challenges you will encounter? This webinar will provide an overview of:

  • Types of research questions that can be addressed with Illumina RNA Sequencing
  • Study design considerations
  • Bioinformatic tools for RNA Sequencing data analysis

This webinar will highlight examples of recent and innovative applications of Illumina RNA sequencing technology. We will also cover the basics of RNA sequencing study design, including how to decide on sampling depth, read length, and paired end versus single read sequencing. In addition, we will discuss the use of TopHat, Cufflinks and related open-source software for the analysis of Illumina RNA sequencing data.

MAY 2011 10
The ClinSeq Project: An Approach to Clinical Genomics Research.
More Info +

Leslie G. Biesecker, M.D.
Sr. Investigator and Head, Human Development Section, Laboratory of Genetic Disease Research, NHGRI, NIH
Flavia M. Facio, M.S., CGC
Genetic Counselor, Genetic Disease Research Branch, NHGRI, NIH

Advances in DNA sequencing platforms along with rapid and dramatic reductions in cost have propelled us into an era where we can begin to contemplate a vision of genomic medicine. NextGen sequencing (NGS) technologies can elucidate an enormous amount of variation for a given individual. While most of these variations are benign or of unknown clinical significance, some are associated with a significant increase in risk of disease for the probands and/or their family members. While other genomic technologies focus on common SNP typing, which detects variants associated with small relative risks (typically on the order of 1.2-1.5), the ability to uncover rare variants with high relative risks is a distinct feature of sequencing-based technologies. Additionally, NGS can uncover variants related to conditions for which the proband might not have been considered at high risk a priori based on personal and family medical histories. These distinguishing characteristics of NGS pose new questions and challenges for the practice of medical genetics and genetic counseling.

This session will begin with Dr. Leslie Biesecker providing an overview of the application of NGS technologies for clinical research purposes in the context of an NIH intramural study called ClinSeq™. He will review the scale and the nature of genetic results generated by NGS, and the current challenges of annotating variants detected by NGS for return to research participants or patients. Ms. Flavia Facio will then present data on the motivations and expectations of ClinSeq™ research participants, who represent early adopters of NGS, to pursue their genomic information. We will encourage audience participation through a Q&A period at the end of the session.

MAY 2011 09
CASAVA 1.8, what is new!
More Info +

Lukas Smink, Ph.D.
Product Marketing Manager, Sequencing & Informatics - EMEA, Illumina

This webinar will address all the key changes in CASAVA 1.8 such as:

  • Improvements in the alignment algorithm and its effects
  • Improved indel detection and SNP calling
  • Improved handling of multiplexed samples
  • Improvement in the data output formats

This webinar will help prepare you for the improvements and changes in the Illumina secondary analysis software.

APR 2011 20
My Sample. My Study. MiSeq. Introducing Illumina's personal sequencing system.
More Info +

Rob Tarbox
Sr. Product Manager, Illumina

MiSeq is the latest example of Illumina innovation, combining our proven sequencing technology and a revolutionary workflow to create a cost-effective, highly accurate system for a wide range of next-generation sequencing applications. This presentation will cover these features including: the MiSeq interactive design that supports a "load and go" workflow; on-board data analysis for base calling, quality values, and variant reporting; and the accuracy of Illumina SBS sequencing technology that's been cited in more than 1,400 published papers. In addition to small genome sequencing (fast ChIP-Seq), the MiSeq offers a robust applications roadmap, from amplicon, plasmid, and bacterial genome sequencing, to large genome sequencing, large genome library QC, and structural variation analysis. Supported by Illumina Nextera and TruSeq sample preparation technologies, these applications enable MiSeq to be a flexible next-generation sequencing system for every laboratory.

APR 2011 01
Next Generation Sequencing Software Presentation by Data2Bio
More Info +

Patrick Schnable, Ph.D.
Director, Center for Plant Genomics, Iowa State University
Managing Partner, Data2Bio™

Next Generation Sequencing (NGS) technologies are revolutionizing biology. During this webinar Dr. Schnable of Data2Bio will describe ways in which NGS technology can help you more quickly and efficiently answer biological questions, how to design and analyze NGS-based experiments, and the types of results you can expect from NGS experiments. Data2Bio helps biologists design and analyze NGS experiments. The Data2Bio team includes staff who were early adopters of NGS technologies and who have expertise in computer science, bioinformatics, statistics, genomic technologies, and genetics/biology. A key differentiating feature about Data2Bio's data analysis reports is that they are prepared in a style that is highly accessible to biologists. In addition, these reports include visualization tools that allow biologists to explore their data/results on their own desktop computers.

MAR 2011 24
TruSeq Exome Enrichment: The Technology Behind the Latest Targeted Resequencing Solution
More Info +

David Williamson, Ph.D.
Bioinformatics Scientist 2, Illumina

Providing unique multi-sample enrichment in a single reaction, Illumina’s new TruSeq Exome Enrichment kit offers the most comprehensive and economical targeted enrichment method for exome resequencing. Optimized to integrate seamlessly with the TruSeq DNA Sample Prep solution, TruSeq Exome kit provides unique multi-sample enrichment in a single reaction that dramatically reduces hands-on time and cost per sample. Please join Illumina Scientists to learn more about:

  • Assay biochemistry and workflow
  • Probe design features
  • Content selection and optimization
  • Currently available analysis tools
MAR 2011 01
Eco Software Version 3.0 Training
More Info +

Illumina Technical Support Team

No abstract available.

JAN 2011 19
Introducing the NEW Infinium HD FFPE Sample Solution
More Info +

Alex Helm
Product Manager, Illumina

Learn how to achieve high quality genotype calls from degraded FFPE samples with the new Infinium HD FFPE solution from Illumina.

The problem:

  • Today, there is an enormous amount of valuable genetic data locked in paraffin blocks
  • Experts estimate there are 200 million to 400 million of these samples worldwide
  • Many consist of rare tumor and matched normal tissue and some are very well annotated
  • These samples hold tremendous promise for genotyping studies
  • Attempts to genotype FFPE samples in the past have been unsuccessful due to the damage these samples sustain during the FFPE process

A solution:

  • Using the NEW Infinium HD FFPE solution, researchers can restore damaged FFPE samples and achieve high-quality genotyping calls
  • Now, FFPE samples can provide informative, usable data
DEC 2010 15
Exome Sequencing & Mendelian Genetics
More Info +

Jay Shendure, MD, Ph.D.
Assistant Professor, Department of Genome Sciences, University of Washington

To selectively isolate complex, megabase-scale subsets of a mammalian genome, we are developing aqueous-phase and solid-phase protocols for the multiplex capture of complex, arbitrary genomic subsets. Coupling of these capture methods to second-generation sequencing platforms enables the sensitive and specific discovery of genetic variation within targeted regions. We are particularly interested in resequencing of aggregate ~30 megabases that collectively comprise the “protein-coding genome”, or “exome”. In collaboration with other research groups at the University of Washington, we recently demonstrated a novel strategy to identify the genetic basis of a Mendelian disorder by exome sequencing of a few affected individuals. We have applied this approach to solve several Mendelian disorders, including Miller syndrome and Kabuki syndrome. We are now applying exome sequencing to additional Mendelian diseases as well as to complex traits.

DEC 2010 08
Mining the Cancer Methylome
More Info +

Peter W. Laird, Ph.D.
Director, USC Epigenome Center

Cancer develops not only as a result of genetic mutations and genomic rearrangements, but also as a consequence of numerous epigenetic alterations, including extensive changes in the distribution of DNA methylation throughout the genome. DNA methylation changes contribute directly to cancer by transcriptional silencing of tumor-suppressor genes through promoter CpG island hypermethylation.

As is the case for genetic alterations, some epigenetic events help to drive oncogenesis, while others represent non-functional passenger events. Broad epigenomic analysis of human tumors can reveal relationships between large numbers of epigenetic events and can provide insight into the mechanisms underlying concerted epigenetic change. Genomic loci targeted by Polycomb Group Repressors in embryonic stem cells, and involved in cellular differentiation are predisposed to become methylated in cancer cells, suggesting that an epigenetic block to cellular differentiation may sometimes be an initiating event in carcinogenesis. The very strong associations between distinct epigenetic subtypes, such as CpG Island Methylator Phenotypes (CIMP) and specific somatic genetic events, such as BRAF mutation in colorectal cancer and IDH1 mutation in glioblastoma multiforme are consistent with an early role for DNA methylation alterations, providing a favorable cellular context for the subsequent somatic mutation. For example, colorectal CIMP results in silencing of IGFBP7, which has been implicated in mutant BRAF-induced senescence pathways.

We have used whole genome shotgun bisulfite sequencing to characterize the entire methylome at single base-pair resolution of a primary colorectal adenocarcinoma and matching histologically normal mucosa. We find that cancer-associated changes occur differentially across defined regions of the genome. Epigenomic data are a necessary component for a full understanding of the relationship between alterations in the cancer genome and the origin and clinical diversity of individual tumors.

NOV 2010 18
TruSeq Data Quality and Accuracy
More Info +

Dipesh Risal, Ph.D.
Senior Product Manager, Informatics, Illumina, Inc.

Every Illumina sequencer is powered by TruSeq—the technology that delivers the most accurate human genome sequence at any coverage. During this webinar you’ll learn how TruSeq technology delivers:

  • The most uniform genomic coverage
  • The fewest gaps across genic and non-genic regions
  • The highest percentage of error-free reads
  • The most bases over Q30

TruSeq reagent chemistry delivers the highest quality data across a broad range of applications. Discover the details for yourself.

NOV 2010 16
RNA Sequencing vs. Arrays: Superior Data at a Lower Cost than Arrays
More Info +

Shawn Levy, Ph.D.
Faculty Investigator, Hudson Alpha Institute for Biotechnology

Learn how RNA sequencing data provides:

  • Superior data at a lower cost than arrays
  • Optimized workflows enabling rapid expression profiling
  • Straightforward analysis for data interpretation and comparison
NOV 2010 10
Refining Cardiovascular and Metabolic Genetic Associations using Custom Arrays
More Info +

Benjamin F. Voight, Ph.D.
Research Scientist, Medical Population Genetics, The Broad Institute of Harvard and MIT

During this genotyping webinar, Dr. Voight discussed: Benefits of GWAS and candidate gene analysis; Design details and genotyping strategies of the Metabochip; Initial replication efforts of the Diabetes Genome-wide Replication And Meta-analysis (DIAGRAM) Consortium; Highlights of the 1,000 Genomes Project; Overview of Type 2 Diabetes whole genome sequencing project

NOV 2010 09
Eco Real-Time PCR System Virtual Demonstration Webinar
More Info +

Russell Nofsinger, PhD.
Field Application Scientist
Sandrine Miller, Pharm.D., Ph.D.
Senior Product Manager, PCR

Learn how easy Eco software is; this seminar will help you navigate from a high performance instrument to quality data using an icon-driven user friendly software. From quantification using standard curve or relative quantification to genotyping using High Resolution Melt, you will be amazed what Eco software can get you access to.

OCT 2010 26
RNA Sequencing: Straightforward Data Analysis
More Info +

Cole Trapnell
Postdoctoral Research fellow, Harvard Medical School and the Broad Institute of MIT and Harvard

Learn how RNA sequencing analysis provides: Access to widely adopted, supported, and efficient data analysis tools; The ability to easily perform multiple analyses with the same data set; Familiar format and easy comparison to array data

OCT 2010 20
Illumina Genome Network: Whole Genome Sequencing Services Without Compromise.
More Info +

Tanya Boyaniwsky
Senior Market Manager, Illumina
Jordan Stockton, Ph.D.,
Senior Market Manager, Computational Biology, Illumina

The Illumina Genome Network links researchers interested in conducting large, human whole-genome sequencing projects with leading institutes worldwide that provide highly economical and rapid turnaround sequencing services. Comprised of CSPro® certified organizations with proven expertise in generating high-quality, economical human genome data, the Illumina Genome Network enables individual researchers to complete their genome sequencing projects quickly and confidently.

OCT 2010 05
RNA Sequencing: The Right Choice for Any Lab
More Info +

Christopher E. Mason, Ph.D.,
Assistant Professor, Weill Medical College of Cornell University

Learn how RNA sequencing: offers easy adaptability for any gene expression lab, provides much richer data than gene expression microarrays, enables whole-transcriptome analysis.

SEP 2010 29
Next-gen GWAS. The Scientist Behind SNP Selection
More Info +

Dr. Mike Eberle,
Senior Staff Bioinformatics Scientist, Illumina

Join us for a live webinar featuring Dr. Michael Eberle, Senior Staff Bioinformatics Scientist at Illumina. Dr. Eberle will discuss: Illumina's marker selection strategy, Specific design process of the Omni 2.5 microarray, Illumina's utilization of the publicly available 1,000 Genomes Project data and SNP call sets, Selecting tagSNPs across diverse populations, Insights into the future direction of the Omni product portfolio.

JUL 2010 21
The Continuum of Bovine Genomic Innovation
More Info +

Andre Eggen, Ph.D,
Agrigenomics Sales Specialist, Illumina

Cattle breeding is undergoing a paradigm shift from identifying animals with valuable phenotypes to identifying genes and genetic loci responsible for valuable traits. This paradigm shift is driven by revolutionary new tools that enable scientists, animal breeders and producers to screen large populations and assess genetic variation on a genome-wide basis. Illumina’s genetic analysis tools enable discovery, validation and screening of any variant in any species. Next generation sequencing projects have improved the accuracy of bovine genome builds and identified novel genetic variation across temperate and tropical bovine species, Bos taurus taurus and Bos taurus indicus alike, supported by collaborations between Illumina and world-wide thought leaders in the bovine industry. The BovineSNP50 BeadChip, commercially launched in 2007, has become the standard whole-genome genotyping tool for both the research and industry communities in Cattle. Recently, Illumina added several important genomic tools to create a unique genomic portfolio: BovineHD, a whole-genome genotyping BeadChip with more than 777,000 SNPs for the identification of agriculturally important genes and a deeper implementation of genomic selection and Bovine3K, a genotyping panel to enable broader access of cattle herds to genetic tests for the evaluation of net merit. These tools are enabling breeders world-wide to identify valuable traits quicker, publish faster and be first to market with new and better animals to feed the world.

Agriculture Genomics:GWAS
MAY 2010 05
An Illumina-Demonstrated Method for Sequencing the Complete Transcriptome
More Info +

Gary Schroth, Ph.D.,
Sr. Director, Gene Expression Applications R&D, Illumina
Shujun Luo,
Sr. Staff Scientist, Illumina

Session will introduce an improved solution for the reduction of abundant transcripts in RNA-Seq experiments, based on an Illumina-optimized protocol utilizing duplex-specific nuclease (DSN) from Evrogen. Illumina scientists will provide a brief overview of DSN, will describe the enhancements made to the DSN workflow to optimize its performance for Illumina RNA-Seq, and will demonstrate its utility in a wide range of applications, including ncRNA discovery and FFPE transcriptome profiling.


  • *
  • *
  • *
  • *
  • *